Table 1

Summary of the cases studied

JAK2V617F and CALR mutation status*
CALRMut
SubtypeJAK2V617F+del52ins5Other†JAK2V617F−/CALRWTUnknownTotal
Controls1515
PV55
ET133131939
MF‡18632837
Total36931202796
  • *JAK2V617F and CALR lesions did not coexist (ie, JAK2V617F+ and CALRMut were mutually exclusive).

  • †A single 1 bp deletion was isolated in exon 9 of CALR from an ET trephine.

  • ‡Includes primary myelofibrosis and ET/PV cases having undergone fibrotic transformation.

  • CALR, calreticulin; del52, 52 bp deletion mutation in exon 9 of CALR; ET, essential thrombocythaemia; ins5, 5 bp insertion mutation in exon 9 of CALR; JAK2, Janus activated kinase 2; MF, myelofibrosis; Mut, mutated; PV, polycythaemia vera; WT, wild type.